Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars In Cancer Biology 2017, 52: 103-109. PMID: 29183778, PMCID: PMC5970946, DOI: 10.1016/j.semcancer.2017.11.019.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Non-Small-Cell LungHumansImmunohistochemistryImmunotherapyLung NeoplasmsMolecular Targeted TherapyPractice Guidelines as TopicWorld Health OrganizationConceptsNon-small cell lung carcinomaCell lung carcinomaLung cancerWorld Health OrganizationLung carcinomaSignificant prognostic impactLung cancer patientsRecent large-scale genomic studiesSmall biopsy specimensDriver gene mutationsPrognostic impactCancer patientsBiopsy specimensTargeted therapyOncologic practiceAccurate subclassificationIHC biomarkersImmunohistochemical markersPatient careAccurate diagnosisImmunotherapyTherapyCancerSubclassificationCritical role